EARLY THERAPY WITH GANCICLOVIR (DHPG) FOR CYTOMEGALOVIRUS (CMV) INFECTION - A REPORT OF AN OUTPATIENT-BASED REGIMEN IN 102 CONSECUTIVE ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) PROCEDURES

被引：0
|
作者：
MARTIN, BA [1 ]
ROWE, JM [1 ]
DUERST, RE [1 ]
RAPOPORT, AP [1 ]
LIESVELD, JL [1 ]
PACKMAN, CH [1 ]
DIPERSIO, JF [1 ]
机构：
[1] UNIV ROCHESTER,ROCHESTER,NY 14627
来源：
BLOOD | 1994年 / 84卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A486 / A486
页数：1
相关论文
共 15 条
  • [1] DIRECTED GANCICLOVIR (DHPG) PROPHYLAXIS AGAINST CYTOMEGALOVIRUS (CMV) PNEUMONITIS IN PATIENTS UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANTATION
    SCHROEDER, M
    ESSELL, J
    HARMAN, G
    HALVORSON, R
    DOLAN, M
    CALLANDER, N
    SNYDER, M
    WILKS, S
    ALLERTON, J
    THOMPSON, J
    [J]. BLOOD, 1993, 82 (10) : A425 - A425
  • [2] EARLY TREATMENT OF CMV INFECTIONS IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS WITH FOSCARNET OR GANCICLOVIR
    BACIGALUPO, A
    VANLINT, MT
    TEDONE, E
    MORO, F
    SANNA, MA
    LONGREN, M
    TRESPI, G
    FRASSONI, F
    OCCHINI, D
    GUALANDI, F
    LAMPARELLI, T
    MARMONT, AM
    [J]. BONE MARROW TRANSPLANTATION, 1994, 13 (06) : 753 - 758
  • [3] LEUKOREDUCTION DOES NOT AFFECT CYTOMEGALOVIRUS (CMV) DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANT (ALLO-BMT) RECIPIENTS
    MENOZZI, D
    GALEL, S
    [J]. TRANSFUSION, 1995, 35 (10) : S252 - S252
  • [4] PREVENTION OF PRIMARY CYTOMEGALOVIRUS (CMV) INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANT PATIENTS (BMT PTS) BY CMV-NEGATIVE BLOOD PRODUCTS AND INTRAVENOUS IMMUNOGLOBULIN
    ASH, RC
    BRATANOW, NC
    RAYBOULD, T
    FERRETTI, G
    OLDHAM, K
    GOTTSCHALL, J
    MENITOVE, J
    ASTER, R
    [J]. EXPERIMENTAL HEMATOLOGY, 1987, 15 (05) : 542 - 542
  • [5] CYTOMEGALOVIRUS IMMUNITY AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) - ROLE OF THE CMV IMMUNITY OF THE DONOR IN THE INCIDENCE OF CMV INFECTION IN RECIPIENTS
    RABIANHERZOG, C
    FERCHAL, F
    VARRIN, F
    GLUCKMANN, E
    PEROL, Y
    COLOMBANI, J
    [J]. EXPERIMENTAL HEMATOLOGY, 1982, 10 : 131 - 131
  • [6] SUCCESSFUL TREATMENT OF SERIOUS CYTOMEGALOVIRUS (CMV) DISEASE WITH 9(1,3-DIHYDROXY-2-PROPOXYMETHYL) GUANINE (GANCICLOVIR, DHPG) AND INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN BONE-MARROW TRANSPLANT (BMT) PATIENTS
    BRATANOW, NC
    ASH, RC
    TURNER, PA
    SMITH, R
    HAASLER, G
    CHITAMBAR, C
    HANSEN, R
    CASPER, J
    [J]. EXPERIMENTAL HEMATOLOGY, 1987, 15 (05) : 541 - 541
  • [7] Short duration preemptive therapy with ganciclovir for the management of cytomegalovirus infection after allogeneic bone marrow transplant.
    Baltathakis, I
    Gougopoulou, D
    Kolovou, A
    Kakkas, I
    Axarlis, S
    Karmiris, T
    Karakasis, D
    Skandalis, A
    Harhalakis, N
    Nikoforakis, E
    [J]. BLOOD, 1996, 88 (10) : 3770 - 3770
  • [8] PREVENTION OF PRIMARY CMV INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) PATIENTS BY CMV-NEGATIVE BLOOD PRODUCTS AND ANTI-CMV INTRAVENOUS IMMUNOGLOBULIN (IVIG)
    ASH, RC
    BRATANOW, N
    RAYBOULD, T
    FERRETTI, G
    OLDHAM, K
    MENITOVE, J
    [J]. CLINICAL RESEARCH, 1986, 34 (04): : A913 - A913
  • [9] CYTOMEGALOVIRUS (CMV) INDUCED PANCYTOPENIA IN ALLOGENEIC BONE-MARROW TRANSPLANT (BMT) RECIPIENTS PROPHYLAXED WITH HIGH-DOSE ACYCLOVIR AND INTRAVENOUS IMMUNOGLOBULIN (IV IG)
    ASCENSAO, JL
    BILGRAMI, S
    QUINN, JJ
    ALMEIDA, MG
    TUCK, D
    BERGSTROM, S
    SHANLEY, J
    DAINIAK, N
    DORSKY, D
    POLIQUIN, C
    [J]. EXPERIMENTAL HEMATOLOGY, 1992, 20 (06) : 710 - 710
  • [10] PREVENTATIVE STRATEGIES FOR CYTOMEGALOVIRUS (CMV) INTERSTITIAL PNEUMONITIS (IP) POST ALLOGENEIC BONE-MARROW TRANSPLANT (ALLO-BMT) - A DECISION AND COST-ANALYSIS
    TOZE, CL
    BARNETT, MJ
    KLINGEMANN, HG
    NANTEL, SH
    REECE, DE
    SHEPHERD, JD
    SUTHERLAND, HJ
    PHILLIPS, GL
    [J]. BLOOD, 1994, 84 (10) : A88 - A88
12